
Emily E Hartwell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4855453/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genetic liability for substance use associated with medical comorbidities in electronic health records of African―and Europeanâ€ancestry individuals. Addiction Biology, 2022, 27, e13099.	2.6	9
2	Postâ€ŧreatment effects of topiramate on alcoholâ€related outcomes: A combined analysis of two placebo ontrolled trials. Addiction Biology, 2022, 27, e13130.	2.6	4
3	Alcohol withdrawal in pastâ€year drinkers with unhealthy alcohol use: Prevalence, characteristics, and correlates in a national epidemiologic survey. Alcoholism: Clinical and Experimental Research, 2022, 46, 422-433.	2.4	4
4	Unique and joint associations of polygenic risk for major depression and opioid use disorder with endogenous opioid system function. Neuropsychopharmacology, 2022, 47, 1784-1790.	5.4	2
5	Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data. Addiction, 2022, 117, 2826-2836.	3.3	1
6	A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder. International Journal of Neuropsychopharmacology, 2021, 24, 89-96.	2.1	11
7	Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder. Neuropsychopharmacology, 2021, 46, 1407-1413.	5.4	13
8	World Health Organization risk drinking levels as a treatment outcome measure in topiramate trials. Alcoholism: Clinical and Experimental Research, 2021, 45, 1664-1671.	2.4	7
9	Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder. Drug and Alcohol Dependence, 2021, 225, 108762.	3.2	7
10	Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial. American Journal of Psychiatry, 2021, 178, 818-828.	7.2	18
11	Analysis of genetic and clinical factors associated with buprenorphine response. Drug and Alcohol Dependence, 2021, 227, 109013.	3.2	2
12	Behavioral Economic Demand for Alcohol and Cigarettes in Heavy Drinking Smokers: Evidence of Asymmetric Cross-commodity Reinforcing Value. Nicotine and Tobacco Research, 2021, 23, 748-755.	2.6	5
13	Survey of Addiction Specialists' Use of Medications to Treat Alcohol Use Disorder. Frontiers in Psychiatry, 2020, 11, 47.	2.6	12
14	Systematic review and metaâ€analysis of the moderating effect of rs1799971 in <i>OPRM1</i> , the muâ€opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction, 2020, 115, 1426-1437.	3.3	27
15	Convergence between the Penn Alcohol Craving Scale and diagnostic interview for the assessment of alcohol craving. Addictive Behaviors Reports, 2019, 10, 100198.	1.9	6
16	Pharmacogenetics of alcohol use disorder treatments: an update. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 553-564.	3.3	23
17	Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent. Drug and Alcohol Dependence, 2019, 200, 181-190.	3.2	10
18	A metaâ€analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction, 2019, 114, 1547-1555.	3.3	74

EMILY E HARTWELL

#	Article	IF	CITATIONS
19	State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. American Journal of Drug and Alcohol Abuse, 2019, 45, 124-140.	2.1	76
20	Craving as a DSM-5 Symptom of Alcohol Use Disorder in Non-Treatment Seekers. Alcohol and Alcoholism, 2018, 53, 235-240.	1.6	15
21	Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial. Alcoholism: Clinical and Experimental Research, 2018, 42, 613-623.	2.4	17
22	Relationship between tonic and phasic craving for alcohol. Addictive Behaviors Reports, 2018, 7, 71-74.	1.9	7
23	Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter?. American Journal of Drug and Alcohol Abuse, 2017, 43, 703-710.	2.1	58
24	Mindfulness-Based Relapse Prevention for Stimulant Dependent Adults: A Pilot Randomized Clinical Trial. Mindfulness, 2017, 8, 126-135.	2.8	53
25	Sex Differences in the Association Between Internalizing Symptoms and Craving in Methamphetamine Users. Journal of Addiction Medicine, 2016, 10, 395-401.	2.6	16
26	The Association of Alcohol Severity and Sleep Quality in Problem Drinkers. Alcohol and Alcoholism, 2015, 50, 536-541.	1.6	33
27	Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers. Pharmacology Biochemistry and Behavior, 2015, 134, 92-98.	2.9	18
28	The relationship between methamphetamine and alcohol use in a community sample of methamphetamine users. Drug and Alcohol Dependence, 2014, 142, 127-132.	3.2	35
29	Sleep disturbances and pain among individuals with prescription opioid dependence. Addictive Behaviors, 2014, 39, 1537-1542.	3.0	76
30	Substance use disorders and PTSD: An exploratory study of treatment preferences among military veterans. Addictive Behaviors, 2014, 39, 369-373.	3.0	67
31	Sex moderates stress reactivity in heavy drinkers. Addictive Behaviors, 2013, 38, 2643-2646.	3.0	31